A Case of Recurrent Breast Cancer Undergoing Risk-reducing Salpingo-oophorectomy Owing to Long-term Complete Response to Olaparib

Key Points

• Long-term complete response was achieved in a recurrent breast cancer patient using olaparib, leading to surgical intervention.
• The patient has been receiving olaparib for 9 years and 4 months, marking one of the longest treatments reported.
• Risk-reducing salpingo-oophorectomy and risk-reducing mastectomy were performed on this patient due to the extended efficacy of olaparib.
• This case highlights the need for further exploration of surgical strategies in patients with long-term responses to olaparib.